Browse > Article
http://dx.doi.org/10.5487/TR.2019.35.4.331

Molecular Markers in Sex Differences in Cancer  

Shin, Ji Yoon (Duksung Innovative Drug Center, College of Pharmacy, Duksung Women's University)
Jung, Hee Jin (Duksung Innovative Drug Center, College of Pharmacy, Duksung Women's University)
Moon, Aree (Duksung Innovative Drug Center, College of Pharmacy, Duksung Women's University)
Publication Information
Toxicological Research / v.35, no.4, 2019 , pp. 331-341 More about this Journal
Abstract
Cancer is one of the common causes of death with a high degree of mortality, worldwide. In many types of cancers, if not all, sex-biased disparities have been observed. In these cancers, an individual's sex has been shown to be one of the crucial factors underlying the incidence and mortality of cancer. Accumulating evidence suggests that differentially expressed genes and proteins may contribute to sex-biased differences in male and female cancers. Therefore, identification of these molecular differences is important for early diagnosis of cancer, prediction of cancer prognosis, and determination of response to specific therapies. In the present review, we summarize the differentially expressed genes and proteins in several cancers including bladder, colorectal, liver, lung, and nonsmall cell lung cancers as well as renal clear cell carcinoma, and head and neck squamous cell carcinoma. The sex-biased molecular differences were identified via proteomics, genomics, and big data analysis. The identified molecules represent potential candidates as sex-specific cancer biomarkers. Our study provides molecular insights into the impact of sex on cancers, suggesting strategies for sex-biased therapy against certain types of cancers.
Keywords
Sex difference; Cancer; Sex hormone; Chemotherapy;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Ferlay, J., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 136, 359-386.   DOI
2 Stafford, H.S., Saltzstein, S.L., Shimasaki, S., Sanders, C., Downs, T.M. and Sadler, G.R. (2008) Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J. Urol., 179, 1704-1708.   DOI
3 Roberts, J.C., Li, G., Reitzel, L.R., Wei, Q. and Sturgis, E.M. (2010) No evidence of sex-related survival disparities among head and neck cancer patients receiving similar multidisciplinary care: a matched-pair analysis. Clin. Cancer Res., 16, 5019-5027.   DOI
4 Ozdemir, B.C. and Dotto, G.P. (2019) Sex hormones and anticancer immunity. Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-0137 [Epub ahead of print].   DOI
5 Kim, H.I., Lim, H. and Moon, A. (2018) Sex differences in cancer: epidemiology, genetics and therapy. Biomol. Ther. (Seoul), 26, 335-342.   DOI
6 Cui, C., Yang, W., Shi, J., Zhou, Y., Yang, J., Cui, Q. and Zhou, Y. (2018) Identification and analysis of human sex-biased microRNAs. Genomics Proteomics Bioinformatics, 16, 200-211.   DOI
7 Izbicka, E., Streeper, R.T., Michalek, J.E., Louden, C.L., Diaz, A. 3rd and Campos, D.R. (2012) Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics, 9, 27-35.
8 Liao, J. and McCauley, L.K. (2006) Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev., 25, 559-571.   DOI
9 Hastings, R.H., Laux, A.M., Casillas, A., Xu, R., Lukas, Z., Ernstrom, K. and Deftos, L.J. (2006) Sex-specific survival advantage with parathyroid hormone-related protein in non-small cell lung carcinoma patients. Clin. Cancer Res., 12, 499-506.   DOI
10 Parisi, M., Nuttall, R., Naiman, D., Bouffard, G., Malley, J., Andrews, J., Eastman, S. and Oliver, B. (2003) Paucity of genes on the Drosophila X chromosome showing male-biased expression. Science, 299, 697-700.   DOI
11 Ellegren, H. and Parsch, J. (2007) The evolution of sex-biased genes and sex-biased gene expression. Nat. Rev. Genet., 8, 689-698.   DOI
12 Williams, T.M. and Carroll, S.B. (2009) Genetic and molecular insights into the development and evolution of sexual dimorphism. Nat. Rev. Genet., 10, 797-804.   DOI
13 Liao, Y.J., Liu, S.P., Lee, C.M., Yen, C.H., Chuang, P.C., Chen, C.Y., Tsai, T.F., Huang, S.F., Lee, Y.H. and Chen, Y.M. (2009) Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: Implications of the gender disparity in liver cancer susceptibility. Int. J. Cancer, 124, 816-826.   DOI
14 Yuan, Y., Liu, L., Chen, H., Wang, Y., Xu, Y., Mao, H., Li, J., Mills, G.B., Shu, Y., Li, L. and Liang, H. (2016) Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell., 29, 711-722.   DOI
15 Ellegren, H. and Parsch, J. (2007) The evolution of sexbiased genes and sex-biased gene expression. Nat. Rev. Genet., 8, 689-698.   DOI
16 Mank, J.E. and Avise, J.C. (2009) Evolutionary diversity and turn-over of sex determination in teleost fishes. Sex. Dev., 3, 60-67.   DOI
17 Connallon, T. and Clark, A.G. (2010) Sex linkage, sex-specific selection, and the role of recombination in the evolution of sexually dimorphic gene expression. Evolution, 64, 3417-3442.   DOI
18 Su, A.I., Cooke, M.P., Ching, K.A., Hakak, Y., Walker, J.R., Wiltshire, T., Orth, A.P., Vega, R.G., Sapinoso, L.M., Moqrich, A., Patapoutian, A., Hampton, G.M., Schultz, P.G. and Hogenesch, J.B. (2002) Large-scale analysis of the human and mouse transcriptomes. Proc. Natl. Acad. Sci. U.S.A., 99, 4465-4470.   DOI
19 Rong, Z., Fan, T., Li, H., Li, J., Wang, K., Wang, X., Dong, J., Chen, J., Wang, F., Wang, J. and Wang, A. (2017) Differential proteomic analysis of gender-dependent hepatic tumorigenesis in Hras12V transgenic mice. Mol. Cell. Proteomics, 16, 1475-1490.   DOI
20 Li, Z., Tuteja, G., Schug, J. and Kaestner, K.H. (2012) Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell, 148, 72-83.   DOI
21 Mato, J.M. and Lu, S.C. (2007) Role of S-adenosyl-L-methionine in liver health and injury. Hepatology, 45, 1306-1312.   DOI
22 Cheng, F. (2016) Gender dimorphism creates divergent cancer susceptibilities. Trends Cancer, 2, 325-326.   DOI
23 Giudicelli, J.F. and Tillement, J.P. (1977) Influence of sex on drug kinetics in man. Clin. Pharmacokinet., 2, 157-166.   DOI
24 Milano, G., Etienne, M.C., Cassuto-Viguier, E., Thyss, A., Santini, J., Frenay, M., Renee, N., Schneider, M. and Demard, F. (1992) Influence of sex and age on fluorouracil clearance. J. Clin. Oncol., 10, 1171-1175.   DOI
25 Sloan, J.A., Goldberg, R.M., Sargent, D.J., Vargas-Chanes, D., Nair, S., Cha, S.S., Novotny, P.J., Poon, M.A., O'Connell, M.J. and Loprinzi, C.L. (2002) Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J. Clin. Oncol., 20, 1491-1498.   DOI
26 Lim, H., Kim, S.Y., Lee, E., Lee, S., Oh, S., Jung, J., Kim, K.S. and Moon, A. (2019) Sex-dependent adverse drug reactions to 5-fluorouracil in colorectal cancer. Biol. Pharm. Bull., 42, 594-600.   DOI
27 Wilson, K. (1984) Sex-related differences in drug disposition in man. Clin. Pharmacokinet., 9, 189-202.   DOI
28 Bonate, P.L. (1991) Gender-related differences in xenobiotic metabolism. J. Clin Pharmacol., 31, 684-690.   DOI
29 Harris, J.R., Tambs, K. and Magnus, P. (1995) Sex-specific effects for body mass index in the new Norwegian twin panel. Genet. Epidemiol., 12, 251-265.   DOI
30 Van Nas, A., Guhathakurta, D., Wang, S.S., Yehya, N., Horvath, S., Zhang, B., Ingram-Drake, L., Chaudhuri, G., Schadt, E.E., Drake, T.A., Arnold, A.P. and Lusis, A.J. (2009) Elucidating the role of gonadal hormones in sexually dimorphic gene coexpression networks. Endocrinology, 150, 1235-1249.   DOI
31 Mittelstrass, K., Ried, J.S., Yu, Z., Krumsiek, J., Gieger, C., Prehn, C., Roemisch-Margl, W., Polonikov, A., Peters, A., Theis, F.J., Meitinger, T., Kronenberg, F., Weidinger, S., Wichmann, H.E., Suhre, K., Wang-Sattler, R., Adamski, J. and Illig, T. (2011) Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet., 7, e1002215.   DOI
32 American Cancer Society (2009) Cancer Facts & Figures 2009, American Cancer Society, Atlanta, pp. 1-5.
33 Xie, Y., Miller, G.G., Cubitt, S.A., Soderlind, K.J., Allalunis-Turner, M.J. and Lown, J.W. (1997) Enediyne-lexitrop-sinDNA-targeted anticancer agents. Physicochemical and cytotoxic properties in human neoplastic cells in vitro, and intracellular distribution. Anticancer Drug Des., 12, 169-179.
34 Dorak, M.T. and Karpuzoglu, E. (2012) Gender differences in cancer susceptibility: an inadequately addressed issue. Front. Genet., 3, 268-276.   DOI
35 Xiao, D., Pan, H., Li, F., Wu, K., Zhang, X. and He, J. (2016) Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma. Oncotarget, 7, 22857-22864.   DOI
36 Baak, J.P., Path, F.R., Hermsen, M.A., Meijer, G., Schmidt, J. and Janssen, E.A. (2003) Genomics and proteomics in cancer. Eur. J. Cancer, 39, 1199-1215.   DOI
37 Parkin, D.M. (2008) The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl., 218, 12-20.   DOI
38 Wilhelm, C.S., Kelsey, K.T., Butler, R., Plaza, S., Gagne, L., Zens, M.S., Andrew, A.S., Morris, S., Nelson, H.H., Schned, A.R., Karagas, M.R. and Marsit, C.J. (2010) Implications of LINE1 methylation for bladder cancer risk in women. Clin. Cancer Res., 16, 1682-1689.   DOI
39 Valdes-Mora, F., Gomez del, P.T., Bandres, E., Cejas, P., Ramirez de Molina, A., Perez-Palacios, R., Gallego-Ortega, D., Garcia-Cabezas, M.A., Casado, E., Larrauri, J., Nistal, M., Gonzalez-Baron, M., Garcia-Foncillas, J. and Lacal, J.C. (2009) TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann. Surg. Oncol., 16, 78-87.   DOI
40 Van der Auwera, I., Bovie, C., Svensson, C., Trinh, X.B., Limame, R., van Dam, P., van Laere, S.J., van Marck, E.A., Dirix, L.Y. and Vermeulen, P.B. (2010) Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer, 10, 97.   DOI
41 Lievre, A., Bachet, J.B., Le Corre, D., Boige, V., Landi, B., Emile, J.F., Cote, J.F., Tomasic, G., Penna, C., Ducreux, M., Rougier, P., Penault-Llorca, F. and Laurent-Puig, P. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res., 66, 3992-3995.   DOI
42 Sasaki, K., Natsugoe, S., Ishigami, S., Matsumoto, M., Okumura, H., Setoyama, T., Uchikado, Y., Kita, Y., Tamotsu, K., Sakamoto, A., Owaki, T. and Aikou, T. (2009) Significance of Twist expression and its association with E-cadherin in esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res., 28, 158.   DOI
43 Mikheeva, S.A., Mikheev, A.M., Petit, A., Beyer, R., Oxford, R.G., Khorasani, L., Maxwell, J.P., Glackin, C.A., Wakimoto, H., Gonzalez-Herrero, I., Sanchez-Garcia, I., Silber, J.R., Horner, P.J. and Rostomily, R.C. (2010) TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol. Cancer, 9, 194.   DOI
44 De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.L., Peeters, M., Humblet, Y., Van Cutsem, E. and Tejpar, S. (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol., 19, 508-515.   DOI
45 Freeman, D.J., Juan, T., Reiner, M., Hecht, J.R., Meropol, N.J., Berlin, J., Mitchell, E., Sarosi, I., Radinsky, R. and Amado, R.G. (2008) Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin. Colorectal Cancer, 7, 184-190.   DOI
46 Wiencke, J.K., Zheng, S., Lafuente, A., Lafuente, M.J., Grudzen, C., Wrensch, M.R., Miike, R., Ballesta, A. and Trias, M. (1999) Aberrant methylation of $p16^{INK4a}$ in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol. Biomarkers Prev., 8, 501-506.
47 Breivik, J., Meling, G.I., Spurkland, A., Rognum, T.O. and Gaudernack, G. (1994) K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br. J. Cancer, 69, 367-371.   DOI
48 Nussler, N.C., Reinbacher, K., Shanny, N., Schirmeier, A., Glanemann, M., Neuhaus, P., Nussler, A.K. and Kirschner, M. (2008) Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Gend. Med., 5, 209-217.   DOI
49 Campbell-Thompson, M., Lynch, I.J. and Bhardwaj, B. (2001) Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res., 61, 632-640.
50 Dehm, S.M. and Bonham, K. (2004) SRC gene expression in human cancer: the role of transcriptional activation. Biochem. Cell Biol., 82, 263-274.   DOI
51 Takemoto, N., Iizuka, N., Yamada-Okabe, H., Hamada, K., Tamesa, T., Okada, T., Hashimoto, K., Sakamoto, K., Takashima, M., Miyamoto, T., Uchimura, S., Hamamoto, Y. and Oka, M. (2005) Sex-based molecular profiling of hepatitis C virus-related hepatocellular carcinoma. Int. J. Oncol., 26, 673-678.
52 Sun, Q.K., Zhu, J.Y., Wang, W., Lv, Y., Zhou, H.C., Yu, J.H., Xu, G.L., Ma, J.L., Zhong, W. and Jia, W.D. (2014) Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med. Oncol., 31, 786-797.   DOI
53 Lehtonen, S.T., Svensk, A.M., Soini, Y., Paakko, P., Hirvikoski, P., Kang, S.W., Saily, M. and Kinnula, V.L. (2004) Peroxiredoxins, a novel protein family in lung cancer. Int. J. Cancer, 111, 514-521.   DOI
54 Paris, P.L., Kupelian, P.A., Hall, J.M., Williams, T.L., Levin, H., Klein, E.A., Casey, G. and Witte, J.S. (1999) Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev., 8, 901-905.
55 Cha, M.K., Suh, K.H. and Kim, I.H. (2009) Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J. Exp. Clin. Cancer Res., 28, 93.   DOI
56 Yang, L., Li, Y., Hong, H., Chang, C.W., Guo, L.W., Lyn-Cook, B., Shi, L. and Ning, B. (2012) Sex differences in the expression of drug-metabolizing and transporter genes in human liver. J. Drug Metab. Toxicol., 3, 1000119.
57 Parkinson, A., Mudra, D.R., Johnson, C., Dwyer, A. and Carroll, K.M. (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol., 199, 193-209.   DOI
58 Tanaka, E. (1999) Gender-related differences in pharmacokinetics and their clinical significance. J. Clin. Pharm. Ther., 24, 339-346.   DOI
59 Scandlyn, M.J., Stuart, E.C. and Rosengren, R.J. (2008) Sex-specific differences in CYP450 isoforms in humans. Expert Opin. Drug Metab. Toxicol., 4, 413-424.   DOI
60 Ou-Yang, D.S., Huang, S.L., Wang, W., Xie, H.G., Xu, Z.H., Shu, Y. and Zhou, H.H. (2000) Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br. J. Clin. Pharmacol., 49, 145-151.   DOI
61 Fitzmaurice, C., Allen, C., Barber, R.M., Barregard, L., Bhutta, Z.A., Brenner, H., Dicker, D.J., Chimed-Orchir, O., Dandona, R., Dandona, L., Fleming, T., Forouzanfar, M.H., Hancock, J., Hay, R.J., Hunter-Merrill, R., Huynh, C., Hosgood, H.D., Johnson, C.O., Jonas, J.B., Khubchandani, J., Kumar, G.A., Kutz, M., Lan, Q., Larson, H.J., Liang, X., Lim, S.S., Lopez, A.D., MacIntyre, M.F., Marczak, L., Marquez, N., Mokdad, A.H., Pinho, C., Pourmalek, F., Salomon, J.A., Sanabria, J.R., Sandar, L., Sartorius, B., Schwartz, S.M., Shackelford, K.A., Shibuya, K., Stanaway, J., Steiner, C., Sun, J., Takahashi, K., Vollset, S.E., Vos, T., Wagner, J.A., Wang, H., Westerman, R., Zeeb, H., Zoeckler, L., Abd-Allah, F., Ahmed, M.B., Alabed, S., Alam, N.K., Aldhahri, S.F., Alem, G., Alemayohu, M.A., Ali, R., Al-Raddadi, R., Amare, A., Amoako, Y., Artaman, A., Asayesh, H., Atnafu, N., Awasthi, A., Saleem, H.B., Barac, A., Bedi, N., Bensenor, I., Berhane, A., Bernabe, E., Betsu, B., Binagwaho, A., Boneya, D., Campos-Nonato, I., Castaneda-Orjula, C., Catala-Lopez, F., Chiang, P., Chibueze, C., Chitheer, A., Choi, J.Y., Cowie, B., Damtew, S., das, N.J., Dey, S., Dharmaratne, S., Dhillon, P., Ding, E., Driscoll, T., Ekwueme, D., Endries, A.Y., Farvid, M., Farzadfar, F., Fernandes, J., Fischer, F., G/Hiwot, T.T., Gebru, A., Gopalani, S., Hailu, A., Horino, M., Horita, N., Husseini, A., Huybrechts, I., Inoue, M., Islami, F., Jakovljevic, M., James, S., Javanbakht, M., Jee, S.H., Kasaeian, A., Kedir, M.S., Khader, Y.S., Khang, Y.H., Kim, D., Leigh, J., Linn, S., Lunevicius, R., El Razek, H.M.A., Malekzadeh, R., Malta, D.C., Marcenes, W., Markos, D., Melaku, Y.A., Meles, K.G., Mendoza, W., Mengiste, D.T., Meretoja, T.J., Miller, T.R., Mohammad, K.A., Mohammadi, A., Mohammed, S., Moradi-Lakeh, M., Nagel, G., Nand, D., Le Nguyen, Q., Nolte, S., Ogbo, F.A., Oladimeji, K.E., Oren, E., Pa, M., Park, E.K., Pereira, D.M., Plass, D., Qorbani, M., Radfar, A., Rafay, A., Rahman, M., Rana, S.M., Soreide, K., Satpathy, M., Sawhney, M., Sepanlou, S.G., Shaikh, M.A., She, J., Shiue, I., Shore, H.R., Shrime, M.G., So, S., Soneji, S., Stathopoulou, V., Stroumpoulis, K., Sufiyan, M.B., Sykes, B.L., Tabares-Seisdedos, R., Tadese, F., Tedla, B.A., Tessema, G.A., Thakur, J.S., Tran, B.X., Ukwaja, K.N., Uzochukwu, B.S.C., Vlassov, V.V., Weiderpass, E., Wubshet, T.M., Yebyo, H.G., Yimam, H.H., Yonemoto, N., Younis, M.Z., Yu, C., Zaidi, Z., Zaki, M.E.S., Zenebe, Z.M., Murray, C.J.L. and Naghavi, M. (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol., 3, 524-548.   DOI
62 Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. CA Cancer J. Clin., 61, 69-90.   DOI
63 Cook, M.B., McGlynn, K.A., Devesa, S.S., Freedman, N.D. and Anderson, W.F. (2011) Sex disparities in cancer mortality and survival. Cancer Epidemiol. Biomarkers Prev., 20, 1629-1637.   DOI
64 Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer statistics. CA Cancer J. Clin., 66, 7-30.   DOI
65 Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre. L.A. and Jemal, A. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 68, 394-424.   DOI
66 Hefaiedh, R., Ennaifer, R., Romdhane, H., Ben, N.H., Arfa, N., Belhadj, N., Gharbi, L. and Khalfallah, T. (2013) Gender difference in patients with hepatocellular carcinoma. Tunis Med., 91, 505-508.
67 Dobruch, J., Daneshmand, S., Fisch, M., Lotan, Y., Noon, A.P., Resnick, M.J., Shariat, S.F., Zlotta, A.R. and Boorjian, S.A. (2016) Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur. Urol., 69, 300-310.   DOI
68 Horstmann, M., Witthuhn, R., Falk, M. and Stenzl, A. (2008) Gender-specific differences in bladder cancer: a retrospective analysis. Gend. Med., 5, 385-394.   DOI
69 Shariat, S.F., Sfakianos, J.P., Droller, M.J., Karakiewicz, P.I., Meryn, S. and Bochner, B.H.. (2010) The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int., 105, 300-308.   DOI
70 Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabarbara, P. and Seymour, L.; National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 353, 123-132.   DOI
71 Matsuda, A., Matsuda, T., Shibata, A., Katanoda, K., Sobue, T. and Nishimoto, H. (2008) Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn. J. Clin. Oncol., 44, 388-396.
72 Jung, K.W., Won, Y.J., Kong, H.J., Oh, C.M., Cho, H., Lee, D.H. and Lee, K.H. (2015) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res. Treat., 47, 127-141.   DOI